BOCA RATON, Fla., Sept. 11, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), today announced that management will not be able to present at the Rodman & Renshaw Global Investment Conference due to the impact of Hurricane Irma. The presentation was to have been made at 4:15 p.m. Eastern time today.
Management still intends to present at the Sidoti & Company Fall 2017 Conference on Thursday, September 28 at 11:25 a.m. This presentation will be webcast live and available for replay in the Investor Relations section of the Company's website at sensushealthcare.com.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit http://www.sensushealthcare.com.
Contact:LHA Investor Relations Kim Sutton Golodetz (212) 838-3777 [email protected]
Advertisement
Management still intends to present at the Sidoti & Company Fall 2017 Conference on Thursday, September 28 at 11:25 a.m. This presentation will be webcast live and available for replay in the Investor Relations section of the Company's website at sensushealthcare.com.
Advertisement
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit http://www.sensushealthcare.com.
Contact:LHA Investor Relations Kim Sutton Golodetz (212) 838-3777 [email protected]
View original content:http://www.prnewswire.com/news-releases/sensus-healthcare-cancels-presentation-to-rodman--renshaw-global-investment-conference-due-to-hurricane-irma-300516834.html
SOURCE Sensus Healthcare
